alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
UNITED STATES OFFICE OF PERSONNEL MANAGEMENT
Washington, DC 20415

Strategic Human
Resources Policy

Division JUL 27 2007

Ms. Nancy Miller

Acting Director, Office of Human Resources
United States Department of Interior

Office of the Secretary

Washington, D.C. 20240

Dear Ms. Miller:

This letter is in response to your request dated June 19, 2007 asking the U.S. Office of Personnel
Management to issue an opinion regarding education requirements. Specifically, your inquiry is
whether or not an agency can use a common listing of academically approved National Wildlife
Coordinating Group (NWCG) courses provided by the American Council on Education (ACE) to
meet at least part of the positive education requirements of the GS-0401 standard.

ACE recommendations do not meet the current requirements of our education policy
incorporated into the Operating Manual for Qualification Standards for General Schedule
Positions on February 15, 2005. ACE recommends credits, but institutions may choose to accept
these recommendations or not. To be acceptable, NWCG courses must receive credit from an
institution with accreditation status from an accrediting body recognized by the Secretary of the
U.S. Department of Education.

As you are aware, you may partner with an accredited institution so that your employees may
receive course credit toward the minimum education requirements of the GS-0401 series.
Although non-accredited training cannot be used for meeting minimum education requirements,
we acknowledge that it may be valuable when evaluating an applicant’s overall qualifications for
a position. As such, it may be considered in the ranking process. If we can be of further
assistance, please contact Daniel Fusco on (202) 606-2226, or at daniel.fusco@opm.gov.

Sincerely,

Nancy H. Kichak
Associate Director
Strategic Human Resources Policy

www.opm.gov ‘Our mission is to ensure the Federal Government has an effective civilian workforce www.usajobs.gov
​

EXHIBIT 10.4
​
[  ]VIA EMAIL
[   ]
​
	 
	Re:
	Retention Bonus 



​
Dear [   ]
We are pleased to inform you that, in recognition of your contributions to Y-mAbs Therapeutics, Inc. (the “Company”), you are being offered the opportunity to receive a retention bonus (the “Retention Bonus”) on the following terms and conditions:
1. Payment of Retention Bonus. Subject to satisfaction of the conditions set forth below, you will be paid a Retention Bonus in the amount equal to 25% of your base cash salary on April 26, 2023 (the “Vesting Date”) payable in a lump sum within thirty (30) days following the Vesting Date.
2. Conditions to Payment. To receive the Retention Bonus, all of the following conditions must be satisfied:
(a) You are still employed with the Company through the Vesting Date;
(b) No notice of termination of your employment has been given by either you or the Company through the Vesting Date; and
(c) the Company’s Biologics License Application for 131I-omburtamab has been approved by the U.S. Food and Drug Administration on or before the Vesting Date.
3. Termination of Employment. If you are not employed with the Company through the Vesting Date for any reason, or if notice of termination of your employment with the Company is made by you or the Company for any reason prior to the Vesting Date (or any other condition set forth in paragraph 2 above is not satisfied), your right to payment of the Retention Bonus will be forfeited in its entirety.
4. Tax Withholding. Payment of the Retention Bonus will be subject to applicable federal, state and local tax withholding.
5. Effect on Other Benefits. You acknowledge that payment of the Retention Bonus is not part of normal or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits, matching contributions or similar payments.
6. Assignment. The obligation to pay the Retention Bonus is solely that of the Company. You may not assign your right to receive the Retention Bonus.
7. No Right to Continued Employment. The grant of this Retention Bonus opportunity does not give you any right to continue your employment relationship with the Company, and you shall remain subject to discharge to the same extent as if this opportunity were not granted to you.
8. Governing Law. Any dispute arising under this letter shall be decided by applying the laws of the State of New York, without regard to conflicts of law principles.
We hope that this arrangement encourages your continued commitment to the Company. Please acknowledge your agreement to the terms of this letter by countersigning it in the space below and returning it to me.
​
Sincerely,
​
	Y-MABS THERAPEUTICS, INC.

	By:
	[ ]
	​

	Name:
	[ ]

	Title:
	[ ]

	​
	​

	ACKNOWLEDGED AND AGREED TO 

	THIS 
	[ ]

	[ ]
	​



​
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
This schedule contains summary financial information extracted from the
financial statements for Anaren Microwave, Inc. submitted with Form 10-K for the
twelve months ended June 30, 2000 and is qualified in its entirety by reference
to such financial statements.
</LEGEND>

<S>                                            <C>
<PERIOD-TYPE>                                  12-MOS
<FISCAL-YEAR-END>                              JUN-30-2000
<PERIOD-START>                                 JUL-01-1999
<PERIOD-END>                                   JUN-30-2000
<CASH>                                            6,179,202
<SECURITIES>                                    133,801,562
<RECEIVABLES>                                    10,992,693
<ALLOWANCES>                                         55,000
<INVENTORY>                                      12,385,125
<CURRENT-ASSETS>                                113,762,076
<PP&E>                                           40,984,070
<DEPRECIATION>                                  (27,647,477)
<TOTAL-ASSETS>                                  189,695,651
<CURRENT-LIABILITIES>                             7,491,250
<BONDS>                                                   0
<PREFERRED-MANDATORY>                                     0
<PREFERRED>                                               0
<COMMON>                                            124,822
<OTHER-SE>                                      179,446,813
<TOTAL-LIABILITY-AND-EQUITY>                    189,695,651
<SALES>                                          60,171,836
<TOTAL-REVENUES>                                 60,171,836
<CGS>                                            35,074,116
<TOTAL-COSTS>                                    48,717,704
<OTHER-EXPENSES>                                          0
<LOSS-PROVISION>                                          0
<INTEREST-EXPENSE>                                   65,999
<INCOME-PRETAX>                                  14,703,799
<INCOME-TAX>                                      5,063,000
<INCOME-CONTINUING>                               9,640,799
<DISCONTINUED>                                            0
<EXTRAORDINARY>                                           0
<CHANGES>                                                 0
<NET-INCOME>                                      9,640,799
<EPS-BASIC>                                            1.07
<EPS-DILUTED>                                          1.00


</TABLE>
[Federal Register Volume 74, Number 108 (Monday, June 8, 2009)]
[Notices]
[Page 27156]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-13280]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


National Center for Injury Prevention and Control Initial Review 
Group, (NCIPC IRG)

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announce the following meeting of the aforementioned 
committee:

    Times and Date: 12:15 p.m.-12:30 p.m., June 30, 2009 (Open)
    12:30 p.m.-2:30 p.m., June 30, 2009 (Closed)
    Place: Teleconference, Toll Free: 888-793-2154, Participant 
Passcode: 4424802.
    Status: Portions of the meetings will be closed to the public in 
accordance with provisions set forth in Section 552b(c)(4) and (6), 
Title 5, U.S.C., and the Determination of the Director, Management 
Analysis and Services Office, CDC, pursuant to Section 10(d) of 
Public Law 92-463.
    Purpose: This group is charged with providing advice and 
guidance to the Secretary, Department of Health and Human Services, 
and the Director, CDC, concerning the scientific and technical merit 
of grant and cooperative agreement applications received from 
academic institutions and other public and private profit and 
nonprofit organizations, including State and local government 
agencies, to conduct specific injury research that focuses on 
prevention and control.
    Matters to be Discussed: The meeting will include the review, 
discussion, and evaluation of individual research cooperative 
agreement applications submitted in response to Fiscal Year 2009 
Requests for Applications related to the following individual 
research announcement: RFA-CD-09-001 ``Translating Research to 
Protect Health through Health Promotion, Prevention, and 
Preparedness (R18)'' for the National Center for Environmental 
Health (NCEH/CDC) applications.
    Agenda items are subject to change as priorities dictate.
    Contact Person for More Information: Jane Suen, Dr.P.H., M.S., 
NCIPC, CDC, 4770 Buford Highway, NE., Mailstop F-62, Atlanta, 
Georgia 30341. Telephone: (770) 488-4281.
    The Director, Management Analysis and Services Office has been 
delegated the authority to sign Federal Register notices pertaining 
to announcements of meetings and other committee management 
activities for both CDC and the Agency for Toxic Substances and 
Disease Registry.

    Dated: May 27, 2009.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. E9-13280 Filed 6-5-09; 8:45 am]
BILLING CODE 4163-18-P
<PAGE>
                                                                               .
                                                                               .
                                                                               .

EXHIBIT 8.1 LIST OF SIGNIFICANT SUBSIDIARIES, JOINTLY CONTROLLED ENTITIES AND
ASSOCIATED COMPANIES OF BRILLIANCE CHINA AUTOMOTIVE AS OF DECEMBER 31, 2007.

<Table>
<Caption>
                                                                          JURISDICTION OF
NAME OF COMPANIES                                                          INCORPORATION
===================================================================       ===============
<S>                                                                       <C>
SUBSIDIARIES

Shenyang Brilliance JinBei Automobile Co., Ltd.                                China
Ningbo Yuming Machinery Industrial Co., Ltd.                                   China
Shenyang XingYuanDong Automobile Component Co., Ltd.                           China
Shenyang Jianhua Motors Engine Co., Ltd.                                       China
Ningbo Brilliance Ruixing Auto Components Co., Ltd.                            China
Mianyang Brilliance Ruian Automotive Components Co., Ltd.                      China
Shenyang JinBei Automotive Industry Holdings Co., Ltd.                         China
Shenyang XinJinBei Investment and Development Co., Ltd.                        China
Shenyang Brilliance Dongxing Automotive Component Co., Ltd.                    China
Shenyang Jindong Development Co., Ltd.                                         China
Shenyang ChenFa Automobile Component Co., Ltd.                                 China
Shanghai Hidea Auto Design Co., Ltd.                                           China
Shenyang Brilliance Power Train Machinery Co., Ltd.                            China
China Brilliance Automotive Components Group Limited                          Bermuda
Southern State Investment Limited                                               BVI
Beston Asia Investment Limited                                                  BVI
Pure Shine Limited                                                              BVI
Key Choices Group Limited                                                       BVI
Brilliance China Automotive Finance Ltd.                                        BVI
Brilliance China Finance Limited                                                BVI

JOINTLY CONTROLLED ENTITIES
Mianyang Xinchen Engine Co., Ltd.                                              China
Shenyang Xinguang Brilliance Automobile Engine Co., Ltd.                       China
BMW Brilliance Automotive Ltd.                                                 China

ASSOCIATED COMPANIES
Shenyang Aerospace Mitsubishi Motors Engine Manufacturing Co., Ltd.            China
Shenyang JinBei Vehicle Dies Manufacturing Co., Ltd.                           China
</Table>
CERTIFICATION
PURSUANT TO
 18
U.S.C. SECTION 1350,
 AS
ADOPTED PURSUANT TO
 SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002
 
 
 In
connection with the quarterly report of Synergx Systems Inc. (the "Company") on
Form 10-QSB for the period ending March 31, 2008 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I, Daniel
S. Tamkin, Chief Executive Officer of the Company, and I, John A. Poserina,
Chief Financial Officer of the Company certify, pursuant to 18 U.S.C. § 1350, as
adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, to my knowledge,
that:
 
 (1)
              The
      Report fully complies with the requirements of Section 13(a) or 15(d) of
      the Securities Exchange Act of 1934;
and
 
 (2)
      The information contained in the Report fairly presents, in all material
      respects, the financial condition and results of operations of the
      Company.
 
 
 /s/DANIEL S. TAMKIN
 Daniel S.
Tamkin
 Chief
Executive Officer
 Synergx
Systems Inc.
 May 14, 2008
  
  /s/JOHN A. POSERINA
 John A.
Poserina
 Chief
Financial  Officer
 Synergx
Systems Inc.
 May 14, 2008
Exhibit 10.3

This sublease ("Sublease") is entered into this 12 day of April 2002, by and between Davox Corporation, located at Six Technology Park Drive,
Westford, MA 01886 ("Sublandlord") and Bio-Imaging Technologies, located at 826 Newtown-Yardley Rd, Newton, PA 18940 ("SubTenant")

---

AGREED
AND ACCEPTED

|Davox Corporation   |  | Bio-Imaging Technologies    
|------------------- |  | ----------------------------
|M. Donovan, SVP Ops |  | Mark L. Weinstein, President
|Print Name & Title  |  | Print Name & Title          
|/s/ M. Donovan      |  | /s/ Mark L. Weinstein       
|Sign                |  | Sign                        
|April 18, 2002      |  | April 12, 2002              
|Date                |  | Date                        

---

QuickLinks
Exhibit 10.21


 


AMENDMENT #3 TO THE PROMISSORY
NOTE


ISSUED ON APRIL 25, 2022


 


THIS AMENDMENT
#3 to the Note (as defined below) (the “Amendment”) is entered into as of August 4, 2022 (the “Effective Date”),
by and between PaxMedica, Inc., a Delaware corporation (the “Company”), and BLUE CANE PARTNERS, LLC, a Delaware limited liability
company (the “Holder”) (collectively the “Parties”).


 


BACKGROUND


 


A.    
The Company and Holder are the parties to that certain senior secured promissory note originally issued by the Company to the Holder on
April 25, 2022, in the original principal amount of $150,000.00 (as amended from time to time, the “Note”); and


 


B.    
The Note was amended on June 9, 2022, and July 11, 2022, and has a principal balance equal to $255,555.55 as of the Effective Date.


 


C.    
The Company has filed with the Securities and Exchange Commission a registration statement on Form S-1 (the "Form S-1") on or
around July 18, 2022, with respect to an underwritten public offering by the Company of its shares of common stock (the “Common
Stock”), and, in connection therewith, the Common Stock are to be listed on the Nasdaq Capital Market ( “Nasdaq” and
the offering, the "Nasdaq Offering"); and


 


		D.	The Parties desire to amend the Note as set forth expressly below.



 


NOW THEREFORE, in consideration of
the execution and delivery of the Amendment and other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Parties agree as follows:


 


1.                
Notwithstanding anything to the contrary in the Note, and so long as the Nasdaq Offering is consummated on or before August 17, 2022,
the balance of the Note shall automatically be converted into a number of shares of Series X preferred stock of the Company on the date
that the Nasdaq Offering is consummated, pursuant to the following formula: the total outstanding balance of the Note divided by 100.


 


2.                
For the avoidance of doubt, if the Nasdaq Offering is not consummated by August 17, 2022, this Amendment shall be null and void and of
no further force or effect.


 


3.                
This Amendment shall be deemed part of, but shall take precedence over and supersede any provisions to the contrary contained in the Note.
Except as specifically modified hereby, all of the provisions of the Note, which are not in conflict with the terms of this Amendment,
shall remain in full force and effect.


 


[Signature page to follow]


 






     


     


    

 


IN WITNESS WHEREOF, the Parties
hereto have executed this Amendment as of the date first above written.


 


	PaxMedica, Inc.	 	BLUE CANE PARTNERS, LLC
	 	 	 
	 	 	 
	By: 	/s/Howard Weisman	 	By:	 /s/Craig Kesselman
	Name:  	Howard Weisman	 	Name:  	Craig Kesselman
	Title: 	Chief Executive Officer	 	Title:	 Member
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THE SCHEDULE  CONTAINS SUMMARY  FINANCIAL  INFORMATION  EXTRACTED FROM WORLDTEX,
INC.  FORM 10-K FOR THE PERIOD  ENDED  DECEMBER 31, 1996 AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER>                                 1,000
<CURRENCY>                                   U.S. Dollars

<S>                                 <C>
<PERIOD-TYPE>                       12-MOS
<FISCAL-YEAR-END>                   DEC-31-1996
<PERIOD-END>                        DEC-31-1996
<EXCHANGE-RATE>                                                 1
<CASH>                                                      2,117
<SECURITIES>                                                0
<RECEIVABLES>                                               39,868
<ALLOWANCES>                                                2,589
<INVENTORY>                                                 37,265
<CURRENT-ASSETS>                                            82,225
<PP&E>                                                      124,660
<DEPRECIATION>                                              34,378
<TOTAL-ASSETS>                                              206,032
<CURRENT-LIABILITIES>                                       34,755
<BONDS>                                                     67,754
<PREFERRED-MANDATORY>                                       0
<PREFERRED>                                                 0
<COMMON>                                                    147
<OTHER-SE>                                                  85,031
<TOTAL-LIABILITY-AND-EQUITY>                                206,032
<SALES>                                                     207,829
<TOTAL-REVENUES>                                            207,829
<CGS>                                                       168,754
<TOTAL-COSTS>                                               168,754
<OTHER-EXPENSES>                                            0
<LOSS-PROVISION>                                            139
<INTEREST-EXPENSE>                                          5,693
<INCOME-PRETAX>                                             17,361
<INCOME-TAX>                                                6,415
<INCOME-CONTINUING>                                         10,946
<DISCONTINUED>                                              0
<EXTRAORDINARY>                                             0
<CHANGES>                                                   0
<NET-INCOME>                                                10,946
<EPS-PRIMARY>                                               .75
<EPS-DILUTED>                                               .73



</TABLE>
AN
x yy
a) z
YY, ae

August 14, 2015
Via email and U.S. Mail

Mr. John Maier

Maier Pfeffer Kim Geary & Cohen LLP
1440 Broadway, Suite 812

Oakland, CA 94612-1520

Re: Review of financing documents for the Federated Indians of Graton
Rancheria

Dear Mr. Maier:

This letter responds to the Federated Indians of Graton Rancheria’s (“Tribe”) request for
the National Indian Gaming Commission’s Office of General Counsel to review a certain
agreement related to a Credit Facility for the Graton Resort & Casino. The Tribe requested an
opinion as to whether the agreement is a management contract requiring the NIGC Chair’s
approval under the Indian Gaming Regulatory Act (IGRA). The Tribe also requested an opinion
on whether the agreement violated IGRA’s requirement that a tribe have the sole proprietary
interest in its gaming operation.

In my review, I considered only the Incremental Joinder and Amendment Agreement
submitted by the parties on August 3, 2015, which was unexecuted, but represented to be in
substantially final form.

The Incremental Joinder and Amendment Agreement contains terms similar to other
agreements the Office of General Counsel has already reviewed and analyzed. Applying the
same analysis here, it is my opinion that the Agreement is not a management contract and does
not require the approval of the Chair. It is also my opinion that it does not violate IGRA’s sole
proprietary interest requirement.

I understand that the Incremental Joinder and Amendment Agreement is in substantially
final form with respect to terms affecting this opinion. If such terms change in any material way
or are inconsistent with assumptions made herein, this opinion shall not apply. Further, this
opinion is limited to the Incremental Joinder and Amendment Agreement. This opinion does not
include or extend to any other agreements.

I anticipate this letter will be posted to the NIGC’s website. Prior to posting, NIGC FOIA
Office will notify you and give you an opportunity to identify and request that information

NEW MAILING ADDRESS: NIGC/DEPARTMENT OF THE INTERIOR 1849 C Street NW, Mail Stop # 1621 Washington, DC 20240 Tel: 202.632.7003 Fox: 202.632.7066

REGIONAL OFFICES Portland, OR; Sacramento, CA; Phoenix, AZ; St. Paul, MN; Tulsa OK; Oklahoma City, OK
WWW.NIGC.GOV


subject to the exemptions under FOIA be redacted or withheld. A list of the FOIA exemptions
may be found at 5 U.S.C. § 552(b).

If you have any questions, please contact NIGC Staff Attorney Andrew Mendoza at (202)
632-7003.

Sincerely,

LM do)

Eric N. Shepard
General Counsel

ce: Greg Sarris, Tribal Chairman